Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N. Allan, Jennifer R. Brown, Javier Pinilla‐Ibarz et al.|Haematologica|2021Cited by 37
Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990Christopher M. McBride, Cynthia M. Shafer, Paul A. Renhowe et al.|Journal of Medicinal Chemistry|2014Cited by 28
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell MalignanciesJohn N. Allan, Jennifer R. Brown, Krish Patel et al.|Blood|2019Cited by 28